Information about Panitumumab
Liver safety of Panitumumab
Panitumumab has been linked to minor serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent liver injury.
Mechanism of action of Panitumumab
Panitumumab (pan” i toom’ ue mab) is a human monoclonal IgG2 antibody to the epidermal growth factor receptor (EGFR, HER1), which is used to treat EGFR-expressing metastatic colorectal cancer. Panitumumab has been shown to induce objective responses in metastatic colorectal cancer and to improve progression free survival. Effects appear to be greater in patients with the wild type as opposed to mutant KRAS status.
FDA approval information for Panitumumab
Panitumumab was approved for use in the United States in 2006 and was the second monoclonal antibody to EGFR approved for use in metastatic colorectal cancer, the other agent being cetuximab (a chimeric mouse-human monoclonal IgG1 antibody) which has a similar profile of efficacy and safety.
Dosage and administration for Panitumumab
Panitumumab is available in liquid solution of 100, 200 and 400 mg in single dose vials (20 mg/mL) under the brand name Vectibix.
Side effects of Panitumumab
The recommended regimen is 6 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity. Skin toxicity is the most common side effect, occurring in 90% of patients and being severe in 16% to 19%. Other side effects include fatigue, abdominal pain, nausea, anorexia, diarrhea, electrolyte disturbance, leukopenia and infections. Less common, but potentially severe side effects include infusion reactions, hypersensitivity reactions, severe skin toxicity, severe diarrhea and dehydration, pulmonary embolism and ocular toxicities.